Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Vistagan; Belgium: Betagan; Czech Republic: Vistagan; France: Betagan; Germany: Vistagan; Greece: Pentila, Vistagan; Hungary: Betagan, Huma Levobulonol, Vistagan; Ireland: Betagan; Italy: Vistagan; Luxembourg: Betagan; Netherlands: Betagan; Poland: Vistagan; Portugal: Betagan; Slovakia: Vistagan; Spain: Betagan; UK: Betagan.

North America

Canada: Betagan, Levobunolol, Probeta; USA: Akbeta, Betagan, Levobunolol.

Latin America

Argentina: Betagan, Levunolol; Brazil: Betagan, B-Tablock; Mexico: Betagan.


Japan: Levobunolol, Mirol.

Drug combinations


Levobunolol Hydrochloride: C~17~H~25~NO~3~ HCl. Mw: 327.85. (1) 1(2H)-Naphthalenone, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro-, hydrochloride, (-)-(S); (2)(-)-(S)-5-[3-(tert-Butylamino)-2-hydroxypropoxy]-3,4-dihydro-1(2H)-naphthalenone hydrochloride. CAS-27912-14-7; CAS-47141-42-4 (levobunolol)(1979).

Pharmacologic Category

Antiglaucoma Agents; β-Adrenergic Blocking Agents. (ATC-Code: S01ED03).

Mechanism of action

Lowers intraocular pressure by reducing aqueous humor production and possibly increases outflow of aqueous humor.

Therapeutic use

To lower intraocular pressure in chronic open-angle glaucoma or ocular hypertension.

Pregnancy and lactiation implications

Unlabeled use


Hypersensitivity to levobunolol or any component of the formulation. Bronchial asthma, severe chronic obstructive pulmonary disease, sinus bradycardia, second- or third-degree AV block, cardiac failure, cardiogenic shock.

Warnings and precautions

Use caution with history of severe anaphylaxis to allergens. In general, patients with bronchospastic disease should not receive β-blockers. Use with caution in diabetes mellitus (may potentiate hypoglycemia and/or mask signs and symptoms). Use with caution in heart failure. Use with caution in myasthenia gravis (may worsen disease). Use with caution in peripheral vascular disease (including Raynaud’s). Use with caution in history of psychiatric illness (may cause or exacerbate CNS depression). Some products contain benzalkonium (caution with contact lens wearers). Ophthalmic solutions contain metabisulfite. Systemic absorption and adverse effects may occur with ophthalmic use, including bradycardia and/or hypotension.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart